Open AccessQuantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab
Author(s) -
Patrick Großmann,
Vivek Narayan,
Ken Chang,
Rifaquat Rahman,
Lauren E. Abrey,
David A. Reardon,
Lawrence H. Schwartz,
Patrick Y. Wen,
Brian M. Alexander,
Raymond Y. Huang,
Hugo J.W.L. Aerts
Publication year - 2017
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nox092
Subject(s) - medicine , imaging biomarker , hazard ratio , magnetic resonance imaging , bevacizumab , cohort , oncology , log rank test , progression free survival , proportional hazards model , population , glioblastoma , radiology , overall survival , confidence interval , chemotherapy , environmental health , cancer research
Anti-angiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of MRI have the potential to noninvasively stratify survival and progression in this patient population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom